28th Mar 2025 10:35
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Result of AGM
28 March 2025 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that all resolutions proposed at the Company's Annual General Meeting, held earlier today, were duly passed.
For further details please contact:
Oxford BioDynamics Plc Iain Ross, Executive Chairman Paul Stockdale, CFO
| +44 (0)1865 518910 |
Shore Capital - Nominated Adviser and Broker Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy
| +44 (0)20 7408 4090 |
WG Partners - Joint Broker David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
| +44 (0)20 3705 9330 |
OAK Securities - Joint Broker Jerry Keen / Henry Clarke / Damion Carruel
| +44 (0)20 3973 3678 |
Camarco - Financial PR Marc Cohen / Tilly Butcher / Fergus Young
| +44 (0)20 3757 4980 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
Related Shares:
Oxford Biodyn